Spots Global Cancer Trial Database for Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Official Title: A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Study ID: NCT00263588
Conditions
Interventions
Study Description
Brief Summary: Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during the course of the study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, San Francisco, California, United States
Novartis Investigative Site, Vallejo, California, United States
Novartis Investigative Site, Denver, Colorado, United States
Novartis Investigative Site, Washington, District of Columbia, United States
Novartis Investigative Site, Boca Raton, Florida, United States
Novartis Investigative Site, Jacksonville, Florida, United States
Novartis Investigative Site, Indianapolis, Indiana, United States
Novartis Investigative Site, Indianapolis, Indiana, United States
Novartis Investigative Site, Sioux City, Iowa, United States
Novartis Investigative Site, Kansas City, Kansas, United States
Novartis Investigative Site, Boston, Massachusetts, United States
Novartis Investigative Site, Ann Arbor, Michigan, United States
Novartis Investigative Site, Minneapolis, Minnesota, United States
Novartis Investigative Site, Saint Louis, Missouri, United States
Novartis Investigative Site, Albuquerque, New Mexico, United States
Novartis Investigative Site, Albuquerque, New Mexico, United States
Novartis Investigative Site, Albuquerque, New Mexico, United States
Novartis Investigative Site, Santa Fe, New Mexico, United States
Novartis Investigative Site, New York, New York, United States
Novartis Investigative Site, Chapel Hill, North Carolina, United States
Novartis Investigative Site, Philadelphia, Pennsylvania, United States
Novartis Investigative Site, Pittsburgh, Pennsylvania, United States
Novartis Investigative Site, Nashville, Tennessee, United States
Novartis Investigative Site, Dallas, Texas, United States
Novartis Investigative Site, Houston, Texas, United States
Novartis Investigative Site, Tyler, Texas, United States
Novartis Investigative Site, Seattle, Washington, United States
Novartis Investigative Site, Yakima, Washington, United States
Novartis Investigative Site, North Sydney, New South Wales, Australia
Novartis Investigative Site, Herston, Queensland, Australia
Novartis Investigative Site, South Brisbane, Queensland, Australia
Novartis Investigative Site, Box Hill, Victoria, Australia
Novartis Investigative Site, Ringwood East, Victoria, Australia
Novartis Investigative Site, Perth, Western Australia, Australia
Novartis Investigative Site, Adelaide, , Australia
Novartis Investigative Site, Salzburg, , Austria
Novartis Investigative Site, Vienna, , Austria
Novartis Investigative Site, Bruxelles, , Belgium
Novartis Investigative Site, Vancouver, British Columbia, Canada
Novartis Investigative Site, Ottawa, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Weston, Ontario, Canada
Novartis Investigative Site, Dijon Cedex, , France
Novartis Investigative Site, Paris Cedex 05, , France
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Toulouse cedex, , France
Novartis Investigative Site, Muenchen, Bayern, Germany
Novartis Investigative Site, Muenchen, Bayern, Germany
Novartis Investigative Site, Frankfurt am Main, Hessen, Germany
Novartis Investigative Site, Neo Faliro, , Greece
Novartis Investigative Site, Bangalore, , India
Novartis Investigative Site, Mumbai, , India
Novartis Investigative Site, Reggio Emilia, Emilia-Romagna, Italy
Novartis Investigative Site, Milano, Lombardia, Italy
Novartis Investigative Site, Perugia, Umbria, Italy
Novartis Investigative Site, Aichi, , Japan
Novartis Investigative Site, Saitama, , Japan
Novartis Investigative Site, Saitama, , Japan
Novartis Investigative Site, Tokyo, , Japan
Novartis Investigative Site, Tokyo, , Japan
Novartis Investigative Site, Tokyo, , Japan
Novartis Investigative Site, Olsztyn, , Poland
Novartis Investigative Site, Warszawa, , Poland
Novartis Investigative Site, Barcelona, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Uppsala, , Sweden
Novartis Investigative Site, Geneve, , Switzerland
Novartis Investigative Site, Locarno, , Switzerland
Novartis Investigative Site, Tainan County, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Manchester, Lancashire, United Kingdom
Novartis Investigative Site, Brighton, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
